← FDA DRUG APPROVALS
FDA ANDA · ANDA089828
ACETAMINOPHEN AND CODEINE PHOSPHATE
Sponsor: STRIDES PHARMA INTL
APPLICATION
ANDA089828
TYPE
ANDA
ORIGINAL APPROVAL
1988-09-30
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
ACETAMINOPHEN AND CODEINE PHOSPHATEPrescription
ACETAMINOPHEN 300MG, CODEINE PHOSPHATE 60MG · TABLET · ORAL
Approval history
2026-06-18REMS · Supplement 44AP
2025-12-22Labeling · Supplement 43 · standardAP
2025-03-28Labeling · Supplement 37 · standardAP
2024-10-31REMS · Supplement 38AP
2023-12-15Labeling · Supplement 36 · standardAP
2021-03-04Labeling · Supplement 35 · standardAP
2019-10-07Labeling · Supplement 32 · standardAP
2019-10-07Labeling · Supplement 33 · standardAP
2018-09-21Labeling · Supplement 30 · standardAP
2018-09-18REMS · Supplement 29 · standardAP
2017-08-29Labeling · Supplement 27 · standardAP
2016-12-16Labeling · Supplement 26 · standardAP
2016-12-16Labeling · Supplement 24 · standardAP
2016-12-16Labeling · Supplement 23 · standardAP
2013-10-18Labeling · Supplement 19 · standardAP
2013-05-10Labeling · Supplement 17 · standardAP
2011-06-22Labeling · Supplement 13AP
2008-02-11Labeling · Supplement 10AP
2007-10-18Labeling · Supplement 8AP
2007-01-10Labeling · Supplement 6AP
1995-03-16Labeling · Supplement 2AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.